Entrada Therapeutics, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $898.0K | $875.0K | $1.3M | $1.6M | $2.0M | $20.6M | $37.4M | $19.6M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $35.4M | $33.1M | $34.0M | $38.4M | $37.9M | $32.1M | $33.4M | $31.3M |
| SG&A Expense | $10.5M | $10.1M | $9.6M | $10.3M | $10.9M | $10.3M | $9.9M | $10.0M |
| Operating Income | $-45.0M | $-42.3M | $-42.2M | $-47.1M | $-46.8M | $-21.8M | $-5.9M | $-21.7M |
| Operating Margin | -5,007.0% | -4,834.6% | -3,249.3% | -2,915.2% | -2,402.5% | -106.0% | -15.7% | -110.7% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | $35.0K | $38.0K | $92.0K | $654.0K | $178.0K | $0 | $-1.9M | $-1.9M |
| Net Income | $-42.8M | $-39.7M | $-39.2M | $-44.1M | $-43.1M | $-17.3M | $1.1M | $-14.0M |
| Net Margin | -4,762.0% | -4,539.1% | -3,014.9% | -2,734.4% | -2,210.4% | -84.4% | 3.0% | -71.7% |
| EPS (Basic) | $-1.01 | $-0.95 | $-0.95 | $-1.06 | $-1.04 | $-0.42 | $-0.20 | $-0.35 |
| EPS (Diluted) | $-1.01 | $-0.95 | $-0.95 | $-1.06 | $-1.04 | $-0.42 | $-0.20 | $-0.35 |
| Shares Outstanding (Basic) | 42.2M | 41.8M | 41.4M | 41.5M | 41.3M | 41.1M | 37.3M | 40.6M |
| Shares Outstanding (Diluted) | 42.2M | 41.8M | 41.4M | 41.5M | 41.3M | 41.1M | 39.0M | 40.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |